Vigabatrin for the treatment of infantile spasms: Final report of a randomized trial

Journal of Child Neurology

Volumn 25, Issue 11, 2010, Pages 1340-1347

  Elterman, Roy D ^a   Shields, W Donald ^b   Bittman, Richard M ^c   Torri, Sarah A ^d   Sagar, Stephen M ^d   Collins, Stephen D ^e  

^a MEDICAL CITY DALLAS HOSPITAL   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

^c Bittman Biostat Inc   (United States)

^d LUNDBECK RESEARCH USA   (United States)

^e NeuroTherapeutics Pharma Inc   (United States)

Author keywords

anticonvulsant; clinical trial; epilepsy; infantile spasms; vigabatrin

Indexed keywords

VIGABATRIN;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DECREASED APPETITE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INFANT; INFANTILE SPASM; INSOMNIA; IRRITABILITY; LETHARGY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPOTONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTICONVULSANTS; CHI-SQUARE DISTRIBUTION; CHILD, PRESCHOOL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; INFANT; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; SINGLE-BLIND METHOD; SPASMS, INFANTILE; TREATMENT OUTCOME; VIGABATRIN;

EID: 78650219192     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073810365103     Document Type: Article

References (22)

1. Lippert B., Metcalf BW, Jung MJ, et al. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur J Biochem. 1977 ; 74: 441-445.
2. John RA, Jones ED, Fowler LJ Enzyme-induced inactivation of transminases by acetylenic and vinyl analogues of 4-aminobutyrate. Biochem J. 1979 ; 177: 721-728.
3. De Biase D., Barra D., Bossa F., et al. Chemistry of the inactivation of 4-aminobutyrate aminotransferase by the antiepileptic drug vigabatrin. J Biol Chem. 1991 ; 266: 20056-20061.
4. Nanavati S., Silverman R. Mechanisms of inactivation of gamma-aminobutyric acid aminotransferase by the antiepilepsy drug gamma-vinyl GABA (vigabatrin). J Am Chem Soc. 1991 ; 113: 9341-9349.
5. Aicardi J., Mumford JP, Dumas C., et al. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia. 1996 ; 37: 638-642.
6. Appleton RE, Peters AC, Mumford JP, et al. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia. 1999 ; 40: 1627-1633.
7. Chiron C., Dulac O., Beaumont D., et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol. 1991 ; Suppl 2: S52 - S59.
8. Chiron C., Dumas C., Jambaque I., et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997 ; 26: 389-395.
9. Vigevano F., Cilio MR Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia. 1997 ; 38: 1270-1274.
10. Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001 ; 57: 1416-1421.
11. Kivity S., Lerman P., Ariel R., et al. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia. 2004 ; 45: 255-262.
12. Goh S., Kwiatkowski DJ, Dorer DJ, et al. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology. 2005 ; 65: 235-238.
13. Hamano S., Yoshinari S., Higurashi N., et al. Developmental outcomes of cryptogenic West syndrome. J Pediatr. 2007 ; 150: 295-299.
14. Camposano SE, Major P., Halpern E., et al. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008 ; 49: 1186-1191.
15. Hrachovy RA, Glaze DG, Frost JD Jr. A retrospective study of spontaneous remission and long-term outcome in patients with infantile spasms. Epilepsia. 1991 ; 32: 212-214.
16. Snead O., Chiron C. Medical treatment. In: Dulac O, Chugani H, Bernardina B, eds. Infantile Spasms and West Syndrome. Philadelphia: WB Saunders; 1994: 244-256.
17. Overby PJ, Kossoff EH Treatment of infantile spasms. Curr Treat Options Neurol. 2006 ; 8: 457-464.
18. Riikonen R., Donner M. ACTH therapy in infantile spasms: side effects. Arch Dis Child. 1980 ; 55: 664-672.
19. Lux AL, Edwards SW, Hancock E., et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004 ; 364: 1773-1778.
20. Lux AL, Edwards SW, Hancock E., et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005 ; 4: 712-717.
21. Darke K., Edwards S., Hancock E., et al. UK Infantile Spasms Study: neurodevelopmental outcome at 4.2 years of age. British Paediatric Neurology Association, Bristol, UK, January 2006. Dev Med Child Neurol. 2006 ; 48 (Suppl 104). 37.
22. Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol. 2004 ; 19: 401-404.